Ikena stockholders approve Inmagene merger; 1:12 reverse split; combined co. to trade as IMA

ImageneBio, Inc.

All 7 proposals approved including merger issuance of IKNA shares >20% and reverse split.
1-for-12 reverse stock split to reduce outstanding shares from ~48.2M to ~4M.
Merger and concurrent financing expected to close around end of July 2025.
Combined company will be ImageneBio, Inc., trading on Nasdaq under ticker IMA.
New CUSIP for post-split common stock: 45175G 207.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.